BridgeBio, US FDA Approves Clinical Trial Plan for BBT-176 Phase 1/2
[Asia Economy Reporter Bomryeong Kim] Bridge Biotherapeutics announced on the 20th that it has received approval from the US FDA (Food and Drug Administration) for the clinical phase 1/2 trial plan of the lung cancer targeted anticancer candidate substance 'BBT-176'.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- [Breaking] Two Days Before Strike... Central Labor Relations Commission Chair Park Soogeun Says "Differences Narrowing... Possibility of Agreement"
- Individual Investors Absorb Foreign Sell-Off... Concerns Over Becoming "Cannon Fodder" Emerge
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
Bridge Biotherapeutics stated, "The dose-escalation study, the first stage of the phase 1/2 trial, is planned to commence within this year targeting Korean patients with advanced non-small cell lung cancer," adding, "Subsequently, dose expansion studies will be conducted in the US and Korea."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
